LY 3009120

Drug Profile

LY 3009120

Alternative Names: DP-4978; LSN 3074753; LY-3009120; Pan-Raf Inhibitor - Deciphera/Eli Lilly

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Deciphera Pharmaceuticals; Eli Lilly
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 02 Jun 2017 Adverse events and efficacy data from a phase I trial in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 29 Nov 2016 Pharmacodynamics data from a preclinical study presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top